Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket. A series of experiments employing MS, molecular modeling, site-directed mutagenesis, and 14 C-labeling studies in viable cells unequivocally demonstrate that these compounds selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773. While the compounds are essentially nonreactive in solution, they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket. The molecular orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as determined from docking experiments in a homology-built molecular model of the ATP site. Evidence is also presented to indicate that the compounds interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study. Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses. The activity profile for this compound is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tyrosine Kinase Inhibition: An Approach to Drug Development
Levitzki, A., & Gazit, A. (1995) · Science · doi:10.1126/science.7892601 · Cited by 1,635
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976
Martiny-Baron, G., Kazanietz, M. G., Mischak, H., Blumberg, P. M., Kochs, G., Hug, H., Marmé, D., & Schächtele, C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98335-3 · Cited by 1,565
SISSAOUI, M. (2018) · Archives of Clinical Microbiology · doi:10.4172/1989-8436-c3-011 · Cited by 1,349
The development of versions 3 and 4 of the Cambridge Structural Database System
Allen, F. H., Davies, J. E., Galloy, J. J., Johnson, O., Kennard, O., Macrae, C. F., Mitchell, E. M., Mitchell, G. F., Smith, J. M., & Watson, D. G. (1991) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00002a004 · Cited by 1,308
Contributions of mass spectrometry to peptide and protein structure
Biemann, K. (1988) · Biological Mass Spectrometry · doi:10.1002/bms.1200160119 · Cited by 1,015
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Specificity within the EGF family/ErbB receptor family signaling network
Riese, D. J., & Stern, D. F. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199801)20:1<41::aid-bies7>3.0.co;2-v · Cited by 809
A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Self-citationPinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 769
KLIJN, J. G. M., BERNS, P. M. J. J., SCHMITZ, P. I. M., & FOEKENS, J. A. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-3 · Cited by 597
A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling
Carraway, K. L., & Cantley, L. C. (1994) · Cell · doi:10.1016/0092-8674(94)90564-9 · Cited by 587
Bridges, A. J., Zhou, H., Cody, D. R., Rewcastle, G. W., McMichael, A., Showalter, H. D. H., Fry, D. W., Kraker, A. J., & Denny, W. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9503613 · Cited by 320
Self-citationPrognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
Maurizi, M., Almadori, G., Ferrandina, G., Distefano, M., Romanini, M., Cadoni, G., Benedetti-Panici, P., Paludetti, G., Scambia, G., & Mancuso, S. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.525 · Cited by 250
HER‐2/ neu Signal Transduction in Human Breast and Ovarian Cancer
Reese, D. M., & Slamon, D. J. (1997) · STEM CELLS · doi:10.1002/stem.150001 · Cited by 229
Bivalence of EGF-like ligands drives the ErbB signaling network
Tzahar, E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.16.4938 · Cited by 228
The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
Bartlett, J., Langdon, S., Simpson, B., Stewart, M., Katsaros, D., Sismondi, P., Love, S., Scott, W., Williams, A., Lessells, A., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.53 · Cited by 211
Protein Kinase InhibitorsThe Tyrosine-Specific Protein Kinases
Lawrence, D. S., & Niu, J. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00052-1 · Cited by 198
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma
Gilbertson, R. J., Perry, R., Kelly, P. J., Pearson, A. D. J., & Lunec, J. (1997) · PubMed · doi:10.25405/ncl.34590669 · Cited by 185
Muller, W. J., Arteaga, C. L., Muthuswamy, S. K., Siegel, P. M., Webster, M. A., Cardiff, R. D., Meise, K. S., Li, F., Halter, S. A., & Coffey, R. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5726 · Cited by 147
The type I growth factor receptors in human breast cancer
Rajkumar, T., & Gullick, W. J. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666177 · Cited by 123
Palmer, B. D., Trumpp-Kallmeyer, S., Fry, D. W., Nelson, J. M., Showalter, H. D. H., & Denny, W. A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960789h · Cited by 115
Self-citationRewcastle, G. W., Murray, D. K., Elliott, W. L., Fry, D. W., Howard, C. T., Nelson, J. M., Roberts, B. J., Vincent, P. W., Hollis Showalter, H. D., Winters, R. T., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970641d · Cited by 113
Self-citationSingh, J., Dobrusin, E. M., Fry, D. W., Haske, T., Whitty, A., & McNamara, D. J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960380s · Cited by 107
Self-citationScambia, G., Benedetti-Panici, P., Ferrandina, G., Distefano, M., Salerno, G., Romanini, M., Fagotti, A., & Mancuso, S. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.339 · Cited by 101
Knighton, D. R., Cadena, D. L., Zheng, J., Eyck, L. F. T., Taylor, S. S., Sowadski, J. M., & Gill, G. N. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5001 · Cited by 81
Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation
Burke, C., Lemmon, M. A., Coren, B. A., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1200873 · Cited by 80
Dougall, W. C., Qian, X., & Greene, M. I. (1993) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240530108 · Cited by 78
Fry, D. W., Nelson, J. M., Slintak, V., Keller, P. R., Rewcastle, G. W., Denny, W. A., Zhou, H., & Bridges, A. J. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00242-6 · Cited by 70
Self-citationDecker, S. J. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.4.571 · Cited by 64
Gibson, K. H., Grundy, W., Godfrey, A. A., et al. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)10059-2 · Cited by 55
Clark, S., & Konstantopoulos, N. (1993) · Biochemical Journal · doi:10.1042/bj2920217 · Cited by 54
Identification of Nitration Sites on Surfactant Protein Aby Tandem Electrospray Mass Spectrometry
Greis, K. D., Zhu, S., & Matalon, S. (1996) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.0522 · Cited by 54
Self-citationFry, D. W. (1994) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.3.6.577 · Cited by 49
Self-citationStrategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity.
Fry, D. W., Kraker, A. J., Connors, R. C., Elliott, W. L., Nelson, J., Showalter, H. D. H., & Leopold, W. R. (1994) · PubMed · Cited by 33
Self-citationChapter 16. Recent Advances in Tyrosine Kinase Inhibitors
Fry, D. W. (1996) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60455-8 · Cited by 29
Self-citationSpada, A. P., & Myers, M. R. (1995) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.5.8.805 · Cited by 25
Inhibitors of protein tyrosine kinases
Fry, D. W., & Bridges, A. J. (1995) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(95)80109-x · Cited by 25
Self-citation
Cited by
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
“The use of irreversible inhibitors has previously been shown to be a viable method to achieve potent and selective inhibition of kinase enzymes (22, 23).”
Method
Metadata
- Authors
- Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., McNamara, D. J., Nelson, J. M., Sherwood, V., Smaill, J. B., Trumpp-Kallmeyer, S., & Dobrusin, E. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-09-29
- Volume
- 95
- Issue
- 20
- Pages
- 12022-12027
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2116398087
- Cited by
- 418
- References
- 38
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.